Revenue
2018
2019
2020
2021
2022
2023
2024
2025
UroGen Pharma Ltd. (URGN)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $109.8M | $90.4M | $82.7M | $64.4M | $48.0M | $11.8M | $18,000 | $1.1M | $8.2M | $17.5M | — |
| Gross profit | $97.3M | $81.5M | $73.4M | $56.7M | $42.9M | $10.8M | $18,000 | −$675,000 | $7.6M | $17.5M | — |
| Research & development | $67.1M | $57.1M | $45.6M | $52.9M | $47.6M | $47.3M | $49.3M | $36.9M | $18.7M | — | — |
| Operating expenses | — | — | — | — | — | — | $109.5M | $76.5M | $27.5M | — | — |
| Operating income | −$124.9M | −$96.8M | −$65.5M | −$79.0M | −$92.3M | −$126.7M | −$109.5M | −$77.2M | −$19.9M | $798,000 | −$12.4M |
| EBITDAderived | −$124.6M | −$96.5M | −$64.7M | −$78.1M | −$91.5M | −$126.3M | −$109.2M | −$76.8M | −$19.8M | $998,000 | — |
| Net income | −$153.5M | −$126.9M | −$102.2M | −$109.8M | −$110.8M | −$128.5M | −$105.1M | −$75.7M | −$20.0M | −$1.9M | −$12.7M |
| Basic EPSper diluted share | -$3.19 | -$2.96 | -$3.55 | -$4.81 | -$4.96 | -$5.90 | -$5.12 | -$4.80 | -$2.14 | -$1.91 | -$5.88 |
| Diluted EPSper diluted share | — | — | — | — | -$4.96 | -$5.90 | -$5.12 | -$4.80 | -$2.14 | -$1.91 | -$5.88 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 22, 2026Form 4 · 10b5-1 | Schoenberg MarkChief Medical Officer | SellOrdinary Shares | 10.0K | $35.01 | $350.1K | 129.8K |
| Jun 8, 2026Form 4 | Schoenberg MarkChief Medical Officer | SellOrdinary Shares | 5.2K | $27.30 | $142.6K | 139.8K |
| May 8, 2026Form 4 · 10b5-1 | Schoenberg MarkChief Medical Officer | SellOrdinary Shares | 10.0K | $30.00 | $300.0K | 135.0K |
| Feb 3, 2026Form 4 | Smith Jason DrewGeneral Counsel | SellOrdinary Shares | 3.2K | $19.69 | $63.3K | 55.6K |
| Feb 3, 2026Form 4 | Smith Jason DrewGeneral Counsel | SellOrdinary Shares | 1.6K | $19.69 | $31.7K | 51.3K |